Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 19/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17377205 | 0.88 | FFAR2 (0.48) | FFAR2KDM4EALDH1A1GAA | |
| SCHEMBL17377197 | 0.88 | KDM4E (0.51) | FFAR2KDM4EALDH1A1GAA | |
| SCHEMBL19742998 | 0.85 | FFAR2 (0.47) | FFAR2KDM4EALDH1A1GAA | |
| SCHEMBL17379284 | 0.84 | FFAR2 (0.51) | FFAR2KDM4EALDH1A1GAA | |
| SCHEMBL17377296 | 0.84 | FFAR2 (0.51) | FFAR2KDM4EALDH1A1GAA | |
| SCHEMBL19743056 | 0.81 | KDM4E (0.47) | FFAR2KDM4EALDH1A1GAA | |
| SCHEMBL19743026 | 0.79 | KDM4E (0.56) | FFAR2KDM4EALDH1A1GAA | |
| SCHEMBL17379343 | 0.79 | KDM4E (0.45) | FFAR2KDM4EALDH1A1GAA | |
| SCHEMBL19742970 | 0.78 | KDM4E (0.50) | FFAR2KDM4EALDH1A1GAA | |
| SCHEMBL17377199 | 0.75 | KDM4E (0.47) | FFAR2KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369492-A1 | 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE | TAKEDA PHARMACEUTICALS CO (JP) | 2017-12-28 | — | — | US | claimed |
| US-20170369492-A1 | 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE | TAKEDA PHARMACEUTICALS CO (JP) | 2017-12-28 | — | — | US | disclosed |
| US-20170369492-A1 | 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE | TAKEDA PHARMACEUTICALS CO (JP) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369492-A1 | 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE | GPR119, IDO1, IDO2 | FFAR2 380/4885KDM4E 556/4885ALDH1A1 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.